๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C

โœ Scribed by Robert Roomer; Bettina E. Hansen; Harry L.A. Janssen; Robert J. de Knegt

Book ID
116652183
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
507 KB
Volume
53
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Risk factors for infection during treatm
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
โœ Robert Roomer; Bettina E. Hansen; Harry L. A. Janssen; Robert J. de Knegt ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 136 KB ๐Ÿ‘ 2 views

Neutropenia during treatment with peginterferon alfa and ribavirin for chronic hepatitis C virus (HCV) infection is a common cause of dose reductions of peginterferon alfa. These reductions are performed to prevent bacterial and fungal infections, which are common during HCV treatment and can be att

Peginterferon alfa-2b plus ribavirin tre
Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C
โœ Stefan Wirth; Heidrun Pieper-Boustani; Thomas Lang; Antje Ballauff; Ulrike Kullm ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 107 KB ๐Ÿ‘ 2 views

Peginterferon plus ribavirin is standard therapy for adults with chronic hepatitis C. As no data are available for children, the aim of the study was to evaluate the efficacy and tolerability of peginterferon alfa-2b in combination with ribavirin in chronically infected children. Genotypes, alanine